HM Payson & Co’s Apellis Pharmaceuticals APLS Stock Holding History

HM Payson & Co’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200	Closed	-$8.05K	–	1143
2026 Q1	$8.05K	Buy	+200	New	+$4.31K	﹤0.01%	934

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HM Payson & Co's APLS Position: Q2 2026 in Review

HM Payson & Co sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 200 shares — an estimated $8.05K sold.

HM Payson & Co first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $8.05K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

HM Payson & Co reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HM Payson & Co sold 200 Apellis Pharmaceuticals shares in Q2 2026, an estimated $8.05K.
HM Payson & Co first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
HM Payson & Co's Apellis Pharmaceuticals position peaked at $8.05K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.